<DOC>
	<DOCNO>NCT02286492</DOCNO>
	<brief_summary>The objective program provide access TAS-102 patient metastatic colorectal cancer refractory fail standard chemotherapy , new therapy TAS-102 therapy TAS-102 clinically indicate .</brief_summary>
	<brief_title>Expanded Access Study TAS-102 Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This open-label study provide expand access TAS-102 prior commercial availability patient metastatic colorectal cancer previously treat , candidate fluoropyrimidine- , irinotecan- , oxaliplatin-based chemotherapy , anti-vascular endothelial growth factor ( VEGF ) therapy , anti-epidermal growth factor receptor ( EGFR ) therapy . Serious adverse event information ( whether relate TAS-102 ) well report pregnancy , overdose , medication error report . In addition , grade adverse drug reaction ( ADRs , adverse event relate study medication ) adverse event result treatment discontinuation record study data CRFs .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Has provide write informed consent 2 . Has adenocarcinoma colon rectum 3 . Has fail least 2 prior regimen standard chemotherapy metastatic colorectal cancer 4 . ECOG performance status 0 1 5 . Is able take medication orally 6 . Has adequate organ function ( bone marrow , kidney liver ) 7 . Women childbearing potential must negative pregnancy test must agree adequate birth control conception possible . Males must agree adequate birth control . 1 . Certain serious illness medical condition ( ) 2 . Has certain recent treatment e.g . major surgery , anticancer therapy , extend field radiation , receive investigational agent , within specified time frame prior study drug administration 3 . Has receive TAS102 4 . Has unresolved toxicity great equal CTCAE Grade 2 attribute prior therapy 5 . Is pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>